

## COMPANY REPORT :                      AEterna Zentaris Inc

### COMPANY SUMMARY

<b>Company name</b>	AEterna Zentaris Inc
<b>Registered Office</b>	1405 du Parc-Technologique Blvd Quebec QUEBEC , G1P 4P5 CANADA
<b>Web site</b>	<a href="http://www.aezsinc.com">http://www.aezsinc.com</a>
<b>Update date</b>	04-JAN-2012
<b>Reason for update</b>	1 Reference Added [1251756 ]

### NEWS

Date	Title
03-JAN-2012	Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan
13-DEC-2011	Aeterna Zentaris: Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
12-DEC-2011	Aeterna Zentaris: Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
09-DEC-2011	Aeterna Zentaris Presents Positive Preclinical Data in Breast Cancer on AEZS-131, a Highly Selective Erk 1/2 Inhibitor, at San Antonio Breast Cancer Symposium
05-DEC-2011	Aeterna Zentaris: Presentations on Perifosine Scheduled at Upcoming ASH Meeting in San Diego, California

### SHARE INFORMATION

<b>Close Price (CAD)</b>	1.58
<b>Change</b>	-0.01 (-0.63%)
<b>Prev Close</b>	1.59

<b>Volume (1,000s)</b>	24
<b>52 Week High</b>	2.56
<b>52 Week Low</b>	1.4
<b>Date</b>	04-JAN-12
<b>Exchange</b>	TORONTO SE

<b>Current Number of Shares Outstanding</b>	103593973
<b>Current Market Capitalization</b>	161606597.88
<b>EPS (Date Reported)</b>	-0.32

## OVERVIEW

### Summary

AEterna Zentaris Inc (formerly AEterna Laboratories Inc (Laboratories AEterna)), formed in 1991, is a global biopharmaceutical company headquartered in Canada. The company is focused on the discovery and development of drugs for the potential treatment of endocrine disorders and cancer.

In May 2004, AEterna Laboratories changed its name to AEterna Zentaris [540684].

### Company Location

Following the acquisition of Echelon Biosciences in January 2005, AEterna Zentaris had operations in Salt Lake City, UT [578527].

In June 1998, the company began construction of a \$16 million Development and Production Center in the Quebec Metro High Tech Park, Canada, which would combine the company's laboratory and production facilities and its head office. Completion of the facility was expected by May 1999 [289513]. In June 2008, the company sold its Quebec City property for \$7.1 million [920809].

### Acquisitions & spin-offs

In October 2007, AEterna Zentaris reported that it was to divest its non-core assets [835612]. In November 2007, AEterna Zentaris completed the sale of all issued and outstanding shares of its subsidiary Echelon Biosciences to Frontier Scientific, for \$3.2 million, which included \$2.6 million upfront with a \$0.6 million in contingent consideration [856666], [856667].

In January 2007, AEterna completed the distribution of its 11,052,996 shares in Atrium Biotechnologies [754777], [789650]. In October 2006, AEterna completed a secondary offering of 3.485 million subordinate voting shares in Atrium Biotechnologies for \$15.8 each; at that time AEterna owned 36.1 % of Atrium's shares and planned to divest its remaining holding [731791].

In January 2005, AEterna's subsidiary, Atrium Biotechnologies Inc, acquired Multichem Inc for \$23.8 million, \$22.2 million of that in cash. The deal aimed to increase the company's presence on the North American market and in the active ingredients and specialty chemicals sector [581484].

In January 2005, AEterna acquired Echelon Biosciences for \$2.7 million by issuing 443,905 common shares at \$6.11 per share. The total for the transaction could reach \$5.6 million upon achievement of certain milestones through the issuance of additional AEterna Zentaris common shares over 3 years [578527].

In March 2004, AEterna's subsidiary, Atrium Biotechnologies Inc, acquired Pure Encapsulations Inc for CDN \$50 million (US \$37.5 million) in cash. Pure focused on the development, manufacturing and marketing of nutritional supplements [525986].

In March 2003, AEterna announced the merger of its subsidiaries AEterna GmbH and Zentaris AG. The company resulting from the merger was to be called Zentaris GmbH [484245].

In December 2002, AEterna concluded a definitive sales and purchase agreement with Degussa AG to acquire all the outstanding shares of Zentaris AG for EUR 50 million (US \$52.5 million). The Boards of AEterna and Degussa unanimously approved the transaction. AEterna acquired the Zentaris shares through a newly created German subsidiary, AEterna GmbH. The purchase price comprised: EUR 27 million (US \$28.35 million) cash, paid on December 30, 2002; and, EUR 23 million (US \$24.15 million) to be paid upon completion of the merger between AEterna GmbH and Zentaris, in accordance with the terms of the transaction and not later than April 30, 2003 [475158].

### **Licensing agreements**

In May 2006, the University of Montreal agreed to test AEterna's small orally-bioavailable molecules to determine their ability to antagonize the appetite-promotor, ghrelin. The 3-year collaboration had an initial budget of CDN \$1.2 million (US \$1.1 million) [665344].

### **Financial**

In June 2011, AEterna entered into an at-the-market agreement with McNicoll, Lewis & Vlaskow which would allow AEterna to sell up to 9.5 million shares at market prices on the NASDAQ Stock Market over a period of 24 months [1204348]. By September 2011, the company raised gross proceeds of approximately \$9.6 million from the at-the-market agreement. By November 2011, the company raised gross proceeds of approximately \$6.2 million by issuing 3.8 million common shares under the agreement [1238368].

In February 2011, AEterna entered into an at-the-market sales agreement with McNicoll, Lewis & Vlaskow which would allow AEterna to sell up to 12.5 million shares at market prices during a 24 month period. The issuances were not to exceed \$19.8 million [1170218]. During the first quarter of 2011, the company issued around 2.7 million common shares under the at-the-market sales agreement for aggregate gross proceeds of approximately \$5.1 million. In April 2011, a total of around 7.3 million common shares were issued, for the remaining aggregate gross proceeds, of approximately \$14.7 million [1192617].

In June 2010, AEterna planned to raise \$12.1 million from a registered direct offering of 8.8 million shares priced at \$1.3725 per share and warrants to buy 4.4 million shares, exercisable at \$1.3725 per share. The transaction was expected to close by June 18, 2010 [1108242]. Later in June 2010, the offering was closed. The company raised net proceeds of \$11.3 million [1109722].

In April 2010, the company planned to raise \$15 million from the registered direct offering of 11.1 million shares priced at \$1.35 each and warrants to purchase 4.4 million shares with an exercise price of \$1.50 per share [1091050]; later that month, the offering was closed and the company raised gross proceeds of \$15 million (net proceeds of \$13.7 million) [1091951].

In January 2010, AEterna was notified by the NASDAQ that it was non-compliant with the minimum bid price rule and would have until July 20, 2010 to regain compliance or face delisting from the exchange [1070435]. In April 2010, the NASDAQ notified AEterna that it had regained compliance with the minimum bid price listing requirement [1094244].

In October 2009, AEterna raised \$5.5 million from a registered direct offering of units. Each unit consisted of shares and warrants. A total of 4.58 million shares were sold at a price of \$1.20 per share and 5-year warrants to purchase 1.83 million shares at an exercise price of \$1.25 per share were issued [1050524], [1051614].

In June 2009, the company was to raise net proceeds of \$9.25 million from the sale of units comprised of 5,319,149 common shares priced at \$1.88 each and warrants to purchase 1,861,702 shares exercisable for \$2.06 each. The warrants could be exercised after 3 months from issuance and would expire 30 months after that. The placement agent would also receive 30-month warrants to purchase 287,234 shares priced at \$2.35 each and exercisable after 6 months from issuance. The deal was expected to close by June 24, 2009 [1019519]. Later in June 2009, the deal was closed and the company raised \$10 million [1020832].

In October 2008, AEterna was notified that its stock had closed below the NASDAQ Global Market's \$1 minimum bid price. However, at that time, the exchange suspended enforcement of this rule until January 19, 2009, due to the current market conditions [956225]. In April 2009, the company regained compliance [1004327].

In June 2008, the company sold its Quebec City property for \$7.1 million. The money would be used to fund phase III trials of cetorelix [920809].

In December 2006, AEterna Zentaris's shareholders approved its proposed reduction in stated capital and the special distribution of its remaining 11,052,996 subordinate voting shares in Atrium Biotechnologies. AEterna Zentaris's Board decided that the distribution date would be January 02, 2007 with a record date for the special distribution on December 29, 2006. The shares would begin trading on the Toronto Stock Exchange on an "ex-distribution" basis on December 27, 2006. AEterna Zentaris shareholders would receive 0.2079 of a subordinate voting share of Atrium Biotechnologies for each one of their AEterna Zentaris common shares [751955]. In September 2006, AEterna was to sell 3.485 million of its subordinate voting shares in its subsidiary, Atrium Biotechnologies, for \$47 million, or CDN \$15.8 (US \$14.12) per share. This would be 24% of the company's ownership in Atrium. The deal was expected to close on October 10, 2006. AEterna also planned to distribute its remaining 11 million voting shares in the company to its shareholders by the end of 2006, subject to shareholder approval. The funds would be used to develop its pipeline [691594]; in October 2006, closing of the sale was delayed [729659]; later that month, a special meeting of the company's shareholders was to take place on December 15, 2006 to discuss the distribution of its remaining 11 million voting shares. Shareholders would receive 0.2079 of an Atrium subordinate voting share for each AEterna share. At that time, the deal was to be completed in early January 2007, subject to shareholder approval [734411].

In February 2006, the Solidarity Fund and SGF Sante each converted their CDN \$12.5 million (US \$10.8 million) loans to AEterna into 3,477,544 shares of the company's stock. The loans were due to mature on March 31, 2006 [650497], [651001]. In March 2003, AEterna entered into a term loan facility of CDN \$25 million with the Solidarity Fund and SGF Sante. The investors had the option to convert all or part of the loan into subordinate voting shares in AEterna [484245].

In 2005, AEterna changed the reporting of its financial figures from CDN \$ to US \$.

In November 2005, AEterna was removed from the NASDAQ Biotechnology Index [634166]. In May 2004, AEterna was selected to be included in the NASDAQ Biotechnology index, effective May 24, 2004 [538765].

In March 2004, AEterna's Atrium Biotechnologies subsidiary filed a final prospectus with the regulatory authorities in Canada for an IPO and secondary offering of 6.25 million shares at \$12 each for total proceeds of \$75 million [592233].

In March 2004, AEterna adopted a shareholder rights plan, to provide adequate time for the company's Board of Directors and shareholders to assess an unsolicited takeover bid, and to provide the Board of Directors with sufficient time to explore and develop alternatives for maximizing shareholder value. Furthermore, the rights plan provided shareholders with an opportunity to participate in a takeover bid [529493].

In December 2003, AEterna reduced its workforce by 20% as part of a reorganization focused on the clinical development of Neovastat (AE-941) and achieving profitability [517379].

In July 2003, AEterna was planning to issue and sell 4.5 million subordinate voting shares at CDN \$7.90 (US \$5.81) each to institutional investors. The company was also to grant investors options to purchase up to one million additional subordinate voting shares. Gross proceeds of the transaction were expected to be CDN \$35.6 million (US \$26.18) and the transaction was scheduled to close on or after July 24, 2003. The funding raised was to be used by AEterna to continue the development of Neovastat (AE-941), for pipeline development and to support strategic alliances and the acquisition of new technologies [496131]. Later in July 2003, AEterna closed its offering. The gross proceeds were \$35.6 million [498865].

In April 2002, AEterna concluded private placements to SGF Sante, Solidarity Fund QFL and Acqua Wellington Private Placement Fund, for an initial amount of \$57 million. Of this, \$35 million was to be used to acquire new technologies or companies in the cancer field, \$20 million was for the further development of Neovastat, and \$2 million was for general corporate purposes. The private placement to SGF Sante and Solidarity Fund QFL consisted of AEterna issuing 7.3 million subordinate voting shares, at a price of \$7.50 each, as well as 7.3 million warrants. The second private placement to Acqua Wellington consisted of AEterna issuing 266,667 subordinate voting shares, at \$7.50 each, as well as 133,333 warrants exercisable at \$13 each [446783].

In September 2001, AEterna completed a public offering of 1.957 million subordinate voting shares at a price of CDN \$8.00 per share, for gross proceeds of CDN \$15.7 million. In addition, AEterna granted the underwriters an overallotment option to acquire 0.293 million subordinate voting shares at a price of CDN \$8.00 per share, which could be exercised within 60 days [422345].

In August 2001, AEterna filed a short form preliminary prospectus for the sale of subordinate voting shares of AEterna, which were eligible for the Quebec Stock Savings Plan [420533].

In September 2000, AEterna reported that an additional 1 million common shares in Atrium Biotechnologies, totalling \$10 million, have been acquired by SGF Soquia Inc, Fonds de solidarite FTQ and Fonds d'investissement bio-alimentaire [381389].

In June 2000, AEterna was selected to be included on the TSE 300 composite index [371774].

In May 2000, AEterna entered into an agreement to issue and sell 754,717 subordinate voting shares at \$13.25 each and subsequently agreed to issue an additional 301,887 subordinate voting shares at \$13.25 each, extending the size of the financing to 1,056,604 shares for an aggregate of \$14.0 million. AEterna's shares were approved for listing on the NASDAQ National Market and were to begin trading on May 10, 2000, under the ticker symbol 'AELA' [366000], [365579], [365599], [365621]. On May 24, 2000, AEterna Laboratories Inc completed the agreement for the bought deal of 1.056 million subordinate voting shares for gross proceeds of \$14 million [368468].

In January 2000, AEterna raised \$2.5 million from the underwriters of its previous public offering in November 1999, who have exercised their overallotment option by acquiring 375,000 subordinate voting shares of \$6.00 per share [351342].

In June 1998, AEterna received CDN \$614,000 from the Societe Innovatech Quebec et Chaudiere-Appalaches and CDN \$876,000 from the Canadian Ministry of Industry, Commerce, Science and Technology [290043].


In May 1997, AEterna raised \$10 million net proceeds from investors [248434].

## **FINANCIAL PERFORMANCE**

---

### **Sales and income**

---



<b>Currency : CAD</b>	2006	2007	2008	2009	2010
<b>Sales</b>	47	45	41	72	29
<b>Operating income</b>	-26	-38	-66	-21	-26
<b>Net income</b>	8	-34	-64	-28	-24

#### Quarterly earnings update

Period	Sales	Operating Income	Net Income
2011 Q3	9	-7	1
2011 Q2	6	-8	-10
2011 Q1	7	-7	-10
2010 Q4	10	-5	-3
2010 Q3	6	-6	-11
2010 Q2	6	-8	-5
2010 Q1	7	-8	-6

2009 Q4	45	20	14
2009 Q3	10	-11	-13
2009 Q2	10	-14	-15

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-DEC-2012	-0.28	-0.28	-0.30
31-DEC-2013	-0.23	-0.25	-0.26
31-DEC-2014	-0.02	-0.02	-0.02

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-DEC- 2012	1.00	-0.29	-30.26	27.63
31-DEC- 2013	2.00	-0.30	-31.84	33.87
31-DEC- 2014	-	-	-2.76	66.9

## MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% change in shares held	Date
Allianz RCM Wellness Fund	Mutual Fund	United States	892600	0.86	0	0.00	30-NOV-11
Danske Capital Finland Oy	Investment Advisor	Finland	283925	0.27	-117980	-0.29	30-NOV-11
Danske Invest MediLife	Mutual Fund	Finland	283925	0.27	-117980	-0.29	30-NOV-11
Union Investment Group	Investment Advisor	Germany	270000	0.26	-224000	-0.45	31-OCT-11
Allianz RCM Global Intellectual Capital	Mutual Fund	United States	269175	0.26	0	0.00	31-OCT-11



Dimensional Fund Advisors, LP	Investment Advisor	United States	254895	0.24	0	0.00	31-OCT-11
iShares S&P/TSX SmallCap Index Fund	Mutual Fund	Canada	104150	0.10	-1742	-0.02	30-NOV-11
Lotsoff Capital Management Micro Cap Fund	Mutual Fund	United States	16600	0.02	0	0.00	31-OCT-11
Fidelity NASDAQ Composite Index Fund	Mutual Fund	United States	9090	0.01	0	0.00	30-NOV-11
Fidelity NASDAQ Composite Index Tracking Stock	Mutual Fund	United States	6105	0.01	0	0.00	30-NOV-11
John Hancock Funds II International Small Company Fund	Mutual Fund	United States	900	0.00	0	0.00	31-OCT-11

## BALANCE SHEET

Currency : CAD (millions)	2006	2007	2008	2009	2010
<b>Assets</b>					
Cash & ST Investments	71	41	61	40	34
Inventories	6	5	4	5	3
Total Current Assets	118	59	75	52	44
Net Property, Plant & Equipment	16	7	8	5	3
Other Assets	60	56	49	34	28
<b>Total assets</b>	<b>260</b>	<b>122</b>	<b>132</b>	<b>91</b>	<b>76</b>




Liabilities					
Account Payable	8	11	13	9	6
ST Debt &Port LT Debt	1	1	0	0	0
Total Current Liabilities	19	17	18	20	13
Long Term Debt	1	0	0	0	0
Deferred Taxes	13	0	0	0	0
Other Liabilities	0	0	0	0	0
<b>Total liabilities</b>	<b>52</b>	<b>34</b>	<b>106</b>	<b>81</b>	<b>64</b>
Stockholders equity					
Non Equity Reserves	0	0	0	0	0
Minority Interest	0	0	0	0	0
Preferred Stock	0	0	0	0	0
Common Stock	196	30	37	43	60
Treasury Stock	0	0	0	0	0
<b>Total liabilities &amp;stockholders equity</b>	<b>260</b>	<b>122</b>	<b>132</b>	<b>91</b>	<b>76</b>

## PATENT POSITION

### Overview

Company Name	AEterna Zentaris Inc	Industry average
Total number of patents	135	24.7
Granted European patents as percentage of European filings	31.9	33

### Therapy areas vs. industrial average



#### Key product patents

Drug name	Indication	Patent	Expiry dates EP	Expiry dates US
ozarelix	Breast tumor; Endometriosis; Infertility; Prostate hyperplasia; Prostate tumor; Uterus tumor	WO-00168676	12-MAR-21 12-MAR-21	14-MAR-20 12-JAN-21
macimorelin	Growth disorder; Hormone deficiency; Metabolic disorder; Wound healing	WO-00196300	13-JUN-21 13-JUN-21	01-AUG-22 01-AUG-22
ozarelix	Breast tumor; Endometriosis; Prostate hyperplasia; Prostate tumor	WO-00055190	11-MAR-20 11-MAR-20	14-MAR-20 12-JAN-21

## STOCK PERFORMANCE

---

Closing price


1 yearCurrency:CAD




## PRODUCT PORTFOLIO

---

Investigational drugs by therapeutic category ( 20 )



Drugs by stage of development ( 32 )




Strategic drug sales: 2010 vs 2016 in USD (millions)

## DEALS PORTFOLIO

Deal summary for AEterna Zentaris Inc ( All Deals )	
Number of deals where AEterna Zentaris Inc is the primary company	28
Number of deals where AEterna Zentaris Inc is the partnering company	15
Total number of deals	43
Number of companies AEterna Zentaris Inc has deals with	35
Number of primary companies that have deals with AEterna Zentaris Inc where AEterna Zentaris Inc is the partnering company	14
Number of partnering companies that have deals with AEterna Zentaris Inc where AEterna Zentaris Inc is the primary company	22

Deals by therapy area ( 43 ) (All Deals)



powered by

## Company Contacts

### Executive Officers

Chairman President & Chief Executive Senior Vice President & Chief Financial Officer Secretary	Juergen H.L. Ernst Dr. Jurgen Engel Dennis Turpin Elliot Shapiro
---	---

### Licensing Summary

MsChantalGravelDirector, Business Operations 1405 boulevard du Parc-Technologique Quebec G1P 4P5 Canada +1 418 652 8525
--

### Senior Officers

Chairman: Juergen Ernst President & CEO: Dr Juergen Engel Senior VP and CMO: Dr Paul Blake Senior VP, Regulatory Affairs and Quality Assurance: Dr Nicholas J Pelliccione Senior VP and CFO: Dennis Turpin
--

## ASSOCIATED/ SUBSIDIARY COMPANIES

Zentaris GmbH

## CLINICAL TRIALS BY INTERVENTION

Clinical Trials for AE-941					
Condition(s)	Phase	Identifiers	On-going	Start Date	Outcomes
<b>A phase I study evaluating safety, tolerability and efficacy of AE-941 in patients with age-related macular degeneration (AMD)</b>					
Age related macular degeneration	Phase 1 Clinical		Yes	16-SEP-1997	No
<b>A phase I/II study of AE-941 monotherapy in patients with patients with metastatic prostate cancer, refractory to standard therapies</b>					
Hormone refractory prostate cancer	Phase 1/Phase 2 Clinical		No	26-JUN-2001	Yes
<b>A phase I/II study of AE-941 in patients with refractory lung cancer</b>					
Lung tumor	Phase 1/Phase 2 Clinical		No	31-DEC-1999	Yes
<b>A phase I/II, multicenter, open-label, dose-escalation, safety and efficacy study of AE-941 in patients with advanced lung cancer refractory to treatment or for which no standard treatments were available</b>					
Lung tumor	Phase 1/Phase 2 Clinical	CT/AE-941/001	No	31-DEC-1996	Yes
<b>A phase I/II, open-label, multi-center, safety and efficacy study of AE-941 in metastatic lung cancer patients who were no longer responding to therapies</b>					
Lung tumor ; Metastasis	Phase 1/Phase 2 Clinical		No	30-JAN-1998	Yes
<b>AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma</b>					
Multiple myeloma	Phase 2 Clinical	CDR0000068801 ; NCT00022282 ; AETERNA-AE-MM-00-02	No	30-APR-2001	No



<b>A phase I/II, randomized, dose-comparison study to evaluate the safety and efficacy of AE-941 in patients with moderate plaque psoriasis</b>					
Psoriasis	Phase 1/Phase 2 Clinical		No	31-JAN-1998	Yes
<b>A phase I/II, efficacy study of AE-941 in patients with renal cell carcinoma</b>					
Renal cell carcinoma	Phase 1/Phase 2 Clinical		No	29-OCT-2001	Yes
<b>AE-941 in Treating Patients With Metastatic Kidney Cancer</b>					
Renal tumor	Phase 3 Clinical	CDR0000067999 ; No NCT00005995 ; AETERNA-AE-RC-99-02 ; CAN-CCI-ETH-00-32-17 ; CCF-IRB-3664 ; JGH-00023 ; UCMC-0006305 ; UPCC-2800		04-MAY-2000	Yes
<b>A phase I/II, open-label study to evaluate long-term safety and preliminary efficacy of AE-941 in patients with advanced solid tumors, refractory to standard treatment</b>					
Solid tumor	Phase 1/Phase 2 Clinical		No	26-MAR-2001	Yes
<b>A phase III study evaluating the long-term safety, tolerability and efficacy of AE-941 in terminally ill patients with solid tumors, refractory to standard therapies</b>					
Solid tumor	Phase 3 Clinical		No	13-JAN-1997	Yes
<b>Clinical Trials for AEZS-112</b>					
<b>Condition(s)</b>	<b>Phase</b>	<b>Identifiers</b>	<b>On-going</b>	<b>Start Date</b>	<b>Outcomes</b>
<b>A phase I, open-label, dose-escalation, multi-center, intermittent-treatment, safety, efficacy and pharmacokinetic study of ZEN-012 in patients with advanced solid tumors or lymphoma</b>					
Lymphoma ; Solid tumor	Phase 1 Clinical		No	08-JAN-2007	Yes
<b>Clinical Trials for cetorelix</b>					
<b>Condition(s)</b>	<b>Phase</b>	<b>Identifiers</b>	<b>On-going</b>	<b>Start Date</b>	<b>Outcomes</b>

<b>Cetrorelix Pamoate im Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)</b>					
Prostate hyperplasia	Phase 3 Clinical	AEZS-102-Z041 ; NCT00670306	No	31-MAR-2008	Yes
<b>Clinical Trials</b> for doxorubicin-LHRH-conjugate (intravenous, cancer), AEterna Zentaris					
Condition(s)	Phase	Identifiers	On-going	Start Date	Outcomes
<b>An open-label, multicenter, dose-escalation, phase I study to evaluate the safety and pharmacokinetics of iv-administered AN-152 in patients with luteinizing hormone releasing hormone (LHRH) receptor positive ovarian, endometrial or breast cancer</b>					
Breast tumor ; Endometroid carcinoma ; Ovary tumor	Phase 1 Clinical		No	18-JAN-2005	Yes
<b>Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors</b>					
Endometroid carcinoma ; Ovary tumor	Phase 2 Clinical	AEZS-108-040 ; NCT00569257 ; AGO-GYN 5 ; EudraCT No. 2007-002663-26	No	31-DEC-2007	Yes
<b>Clinical Trials</b> for ozarelix					
Condition(s)	Phase	Identifiers	On-going	Start Date	Outcomes
<b>A multicenter, open-label, randomized, controlled, dose-finding, phase II trial to evaluate the safety and efficacy of ozarelix as a treatment for patients with hormone-dependent prostate cancer</b>					
Hormone dependent prostate cancer	Phase 2 Clinical		Yes	11-APR-2005	Yes
<b>A phase IIb study to verify the optimal dosing regimen for ozarelix in patients with hormone-dependent prostate cancer</b>					
Hormone dependent prostate cancer	Phase 2b Clinical		No	02-AUG-2006	No
<b>A double-blind, randomized, placebo-controlled, multicenter, dose-ranging phase II trial to assess the safety and efficacy of ozarelix in patients with benign prostatic hyperplasia</b>					

Prostate hyperplasia	Phase 2 Clinical		No	13-APR-2005	Yes
<b>A phase I, single-dose, dose-escalation study to evaluate the effect of ozarelix, a potential treatment for prostate diseases, on testosterone levels in healthy males</b>					
Prostate hyperplasia ; Prostate tumor	Phase 1 Clinical		No	09-MAY-2003	Yes
<b>Clinical Trials for perifosine</b>					
<b>Condition(s)</b>	<b>Phase</b>	<b>Identifiers</b>	<b>On-going</b>	<b>Start Date</b>	<b>Outcomes</b>
<b>A phase I study of the safety, tolerability and preliminary efficacy of perifosine in combination with radiotherapy in patients with unresectable locally advanced tumors</b>					
Solid tumor	Phase 1 Clinical		No	07-JUN-2004	Yes

## BIBLIOGRAPHY

<b>Number of linked references for : 175</b>
<p><b>990755</b> Financial results Thomson Reuters IDdb Alert , 2009:March 12 , <i>Article type: Commercial</i></p>
<p><b>990715</b> AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results AEterna Zentaris Inc Press Release , 2009:March 11 , <i>Article type: Commercial</i></p>
<p><b>989538</b> Sanofi-aventis and AEterna Zentaris Sign Agreement in the U.S. sanofi-aventis U.S. Press Release , 2009:March 06 , <i>Article type: Commercial</i></p>
<p><b>989531</b> sanofi-aventis agrees to develop AEterna Zentaris' cetorelix in the US for BPH AETERNA ZENTARIS INC Press Release , 2009:March 06 , <i>Article type: Commercial</i></p>
<p><b>983551</b> AEterna Zentaris Inc: Annual report 2007 AEterna Zentaris Inc</p>

Annual Report , 2008:March 04 , <i>Article type: Commercial</i>
<p>982185</p> <p>Patents Journal reports two SPCs surrendered in the UK.</p> <p>Thomson Reuters</p> <p>IDdb Alert , 2009:February 06 , <i>Article type: Commercial</i></p>
<p>970307</p> <p>AEterna Zentaris Completes Patient Recruitment for Safety Trial of Phase 3 Program with Cetorelix in Benign Prostatic Hyperplasia</p> <p>AEterna Zentaris Inc</p> <p>Press Release , 2008:December 11 , <i>Article type: Commercial</i></p>
<p>968240</p> <p>AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for \$52.5 Million to Cowen Healthcare Royalty Partners</p> <p>AETERNA ZENTARIS INC.</p> <p>Press Release , 2008:December 03 , <i>Article type: Commercial</i></p>
<p>967993</p> <p>Appointments</p> <p>Thomson Reuters</p> <p>IDdb Alert , 2008:December 03 , <i>Article type: Commercial</i></p>
<p>963042</p> <p>Products in development</p> <p>AEterna Zentaris Inc</p> <p>Company World Wide Web site , 2008:November 14 , <i>Article type: Commercial</i></p>
<p>962863</p> <p>Financial results</p> <p>Thomson Reuters</p> <p>IDdb Alert , 2008:November 14 , <i>Article type: Commercial</i></p>
<p>962805</p> <p>AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results</p> <p>AEterna Zentaris Inc</p> <p>Press Release , 2008:November 13 , <i>Article type: Commercial</i></p>
<p>920809</p> <p>AEterna Zentaris Sells Quebec City Building for \$7.1 million</p> <p>AEterna Zentaris Inc</p> <p>Press Release , 2008:June 27 , <i>Article type: Commercial</i></p>
<p>459823</p> <p>Zentaris signs extensive licence agreements with Ardana Bioscience</p> <p>Zentaris AG</p> <p>Press Release , 2002:July 10 , <i>Article type: Commercial</i></p>

1251756

Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan

AEterna Zentaris Inc

Press Release , 2012:January 03 , *Article type: Commercial*

1248105

Aeterna Zentaris: Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting

AEterna Zentaris Inc

Press Release , 2011:December 13 , *Article type: Commercial*

1247919

AEterna Zentaris Company website and Pipeline

AEterna Zentaris Inc

Company World Wide Web site , 2011:December 13 , *Article type: Commercial*

1247658

Aeterna Zentaris: Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting

AEterna Zentaris Inc

Press Release , 2011:December 12 , *Article type: Commercial*

1247466

AEZS-131 - a highly selective ERK-inhibitor: Characterization and preclinical testing in triple negative breast cancer (TNBC)

AEterna Zentaris Inc

Company Presentation , 2011:December 08 , *Article type: Commercial*

1247211

Aeterna Zentaris Presents Positive Preclinical Data in Breast Cancer on AEZS-131, a Highly Selective Erk 1/2 Inhibitor, at San Antonio Breast Cancer Symposium

AEterna Zentaris Inc

Press Release , 2011:December 09 , *Article type: Commercial*

1247177

Bio-Europe 2011: Aeterna Zentaris company profile

AEterna Zentaris Inc

Bio-Europe Annual International Partnering Conference , 2011:November 02 , *Article type: Commercial*

1245684

Aeterna Zentaris: Presentations on Perifosine Scheduled at Upcoming ASH Meeting in San Diego, California

AEterna Zentaris Inc

Press Release , 2011:December 05 , *Article type: Commercial*

1243527

Regulatory news in brief

Thomson Reuters

IDdb Alert , 2011:November 29 , *Article type: Commercial*

1243484

Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia

AEterna Zentaris Inc

Press Release , 2011:November 28 , *Article type: Commercial*

1242617

Aeterna Zentaris and Hikma Pharmaceuticals Sign a Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for Middle East and North Africa (MENA) Region

AETERNA ZENTARIS INC

Press Release , 2011:November 23 , *Article type: Commercial*

1240598

Aeterna Zentaris Presents Encouraging Preclinical Data for Disorazol Z (AEZS-137) at AACR-NCI-EORTC Conference

AEterna Zentaris Inc

Press Release , 2011:November 16 , *Article type: Commercial*

1238413

Financial results

Thomson Reuters

IDdb Alert , 2011:November 11 , *Article type: Commercial*

1238368

Aeterna Zentaris Reports Third Quarter 2011 Financial and Operating Results

AEterna Zentaris Inc

Press Release , 2011:November 10 , *Article type: Commercial*

1233230

FDA approves IND for phase II breast cancer trial of AEterna's AEZS-108

AEterna Zentaris Inc

Press Release , 2011:October 25 , *Article type: Commercial*

1230288

Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology

Keryx Biopharmaceuticals Inc

Press Release , 2011:October 13 , *Article type: Commercial*

1228197

Aeterna Zentaris: Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of Perifosine Plus Capecitabine in Patients with Metastatic Colorectal Cancer

AEterna Zentaris Inc

Press Release , 2011:October 05 , *Article type: Commercial*

1225793

A Phase I Trial of AEZS-108 (AN-152) in Castration- and Taxane-Resistant Prostate Cancer

AEterna Zentaris Inc

Company Presentation , 2011:September 24 , <i>Article type: Commercial</i>
<p>1225536</p> <p>Aeterna Zentaris Announces Interim Data for its Phase 1/2 Trial with AEZS-108 in Prostate Cancer at ESMO Congress - AEZS-108 well tolerated at all dose levels / Early evidence of anti-tumor activity</p> <p>Aeterna Zentaris Inc</p> <p>Press Release , 2011:September 23 , <i>Article type: Commercial</i></p>
<p>1222758</p> <p>AGO-GYN 5 –(Phase II) study with AEZS-108, a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer</p> <p>Aeterna Zentaris Inc</p> <p>Company Presentation , 2011:September 14 , <i>Article type: Commercial</i></p>
<p>1222493</p> <p>Aeterna Zentaris Presents Positive Final Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ESGO Meeting in Milan, Italy</p> <p>Aeterna Zentaris Inc</p> <p>Press Release , 2011:September 14 , <i>Article type: Commercial</i></p>
<p>1218653</p> <p>Aeterna Zentaris Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of Perifosine for the Treatment of Refractory Advanced Colorectal Cancer</p> <p>Aeterna Zentaris Inc</p> <p>Press Release , 2011:August 31 , <i>Article type: Commercial</i></p>
<p>1218355</p> <p>Aeterna Zentaris Announces Favorable Top-Line Results of Completed Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency</p> <p>Aeterna Zentaris Inc</p> <p>Press Release , 2011:August 30 , <i>Article type: Commercial</i></p>
<p>1218329</p> <p>Aeterna Zentaris Announces Results of its Novel Orally Active Anticancer Erk Inhibitor at the American Chemical Society National Meeting</p> <p>Aeterna Zentaris Inc</p> <p>Press Release , 2011:August 30 , <i>Article type: Commercial</i></p>
<p>1214186</p> <p>Aeterna Zentaris Reports Second Quarter 2011 Financial and Operating Results</p> <p>Aeterna Zentaris Inc</p> <p>Press Release , 2011:August 10 , <i>Article type: Commercial</i></p>
<p>1214113</p> <p>Financial results</p> <p>Thomson Reuters</p> <p>IDdb Alert , 2011:August 11 , <i>Article type: Commercial</i></p>
1210494



Aeterna Zentaris Announces Completion of Patient Recruitment for Phase 3 Trial with Perifosine in Refractory Advanced Colorectal Cancer

Aeterna Zentaris Inc

Press Release , 2011:July 27 , *Article type: Commercial*

1210299

Aeterna Zentaris Completes Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency

Aeterna Zentaris Inc

Press Release , 2011:July 26 , *Article type: Commercial*

1208731

Aeterna Zentaris Successfully Reached a Key Milestone in the Non-Clinical Development of its Oral Prostate Cancer Vaccine Candidate, AEZS-120

Aeterna Zentaris Inc

Press Release , 2011:July 20 , *Article type: Commercial*

1206962

Aeterna Zentaris Granted Patent for Perifosine by European Patent Office

Aeterna Zentaris Inc

Press Release , 2011:July 12 , *Article type: Commercial*

1204348

Aeterna Zentaris Announces "At-the-Market" Issuance Program

Aeterna Zentaris Inc

Press Release , 2011:June 29 , *Article type: Commercial*

1204177

Company news in brief

Thomson Reuters

IDdb Alert , 2011:June 30 , *Article type: Commercial*

1192672

Financial results

Thomson Reuters

IDdb Alert , 2011:May 19 , *Article type: Commercial*

1192617

Aeterna Zentaris Reports First Quarter 2011 Financial and Operating Results

Aeterna Zentaris Inc

Press Release , 2011:May 18 , *Article type: Commercial*

1181604

Aeterna Zentaris Announces Results on AEZS-131, a Highly Selective Erk 1/2 Inhibitor Anticancer Compound at American Association for Cancer Research Annual Meeting

Aeterna Zentaris Inc

Press Release , 2011:April 05 , *Article type: Commercial*

1181486

Aeterna Zentaris Announces Results On Its Lead Anticancer Agent Perifosine at American Association for Cancer Research Annual Meeting

Aeterna Zentaris Inc

Press Release , 2011:April 04 , *Article type: Commercial*

1178930

Aeterna Zentaris Awarded Grant by German Government to Develop Novel Targeted Anti-Cancer Compounds

AETERNA ZENTARIS INC

Press Release , 2011:March 24 , *Article type: Commercial*

1178440

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2010 Financial and Operating Results

Aeterna Zentaris Inc

Press Release , 2011:March 22 , *Article type: Commercial*

1178380

Financial results

Thomson Reuters

IDdb Alert , 2011:March 23 , *Article type: Commercial*

1174360

Yakult Honsha agrees to develop Aeterna Zentaris' perifosine in Japan

AETERNA ZENTARIS INC

Press Release , 2011:March 09 , *Article type: Commercial*

1171418

Aeterna Zentaris Receives \$2.5 Million Milestone Payment From Cowen Healthcare Royalty Partners

AETERNA ZENTARIS INC

Press Release , 2011:February 28 , *Article type: Commercial*

1170218

Aeterna Zentaris Announces "At-the-Market" Issuance Program

Aeterna Zentaris Inc

Press Release , 2011:February 22 , *Article type: Commercial*

1169973

Company news in brief

Thomson Reuters

IDdb Alert , 2011:February 23 , *Article type: Commercial*

1157018

Regulatory news in brief

Thomson Reuters

IDdb Alert , 2010:December 21 , *Article type: Commercial*

1156919

Aeterna Zentaris Receives Agreement from FDA on Special Protocol Assessment for Solorel (AEZS-130, Macimorelin) to Complete Registration Study for Diagnosis of Adult Growth Hormone Deficiency

<p>AEterna Zentaris Inc Press Release , 2010:December 20 , <i>Article type: Commercial</i></p>
<p>1156094 Aeterna Zentaris Presents Comprehensive R&amp;D Review and 2011 Strategic Outlook in New York City AEterna Zentaris Inc Press Release , 2010:December 14 , <i>Article type: Commercial</i></p>
<p>1154053 Aeterna Zentaris: Phase 2 Data Demonstrate Perifosine's Promising Efficacy in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma AEterna Zentaris Inc Press Release , 2010:December 06 , <i>Article type: Commercial</i></p>
<p>1149004 Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany AEterna Zentaris Inc Press Release , 2010:November 18 , <i>Article type: Commercial</i></p>
<p>1148606 Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany AEterna Zentaris Inc Press Release , 2010:November 17 , <i>Article type: Commercial</i></p>
<p>1147531 AEterna Zentaris Inc Company website and Pipeline AEterna Zentaris Inc Company World Wide Web site , 2010:November 12 , <i>Article type: Commercial</i></p>
<p>1146628 Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results AEterna Zentaris Inc Press Release , 2010:November 09 , <i>Article type: Commercial</i></p>
<p>1146459 Financial results Thomson Reuters IDdb Alert , 2010:November 10 , <i>Article type: Commercial</i></p>
<p>1136593 Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD) AEterna Zentaris Inc Press Release , 2010:October 05 , <i>Article type: Commercial</i></p>
<p>1124040</p>

<p>Aeterna Zentaris Reports Second Quarter 2010 Financial and Operating Results  Aeterna Zentaris Inc  Press Release , 2010:August 12 , <i>Article type: Commercial</i></p>
<p>1124014  Financial results  Thomson Reuters  IDdb Alert , 2010:August 13 , <i>Article type: Commercial</i></p>
<p>1121609  Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108  AETERNA ZENTARIS INC  Press Release , 2010:August 05 , <i>Article type: Commercial</i></p>
<p>1116161  Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma  Aeterna Zentaris Inc  Press Release , 2010:July 14 , <i>Article type: Commercial</i></p>
<p>1116073  Regulatory news in brief  Thomson Reuters  IDdb Alert , 2010:July 15 , <i>Article type: Commercial</i></p>
<p>1111456  Regulatory news in brief  Thomson Reuters  IDdb Alert , 2010:June 30 , <i>Article type: Commercial</i></p>
<p>1111419  Aeterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Trial with Perifosine in Colorectal Cancer  Aeterna Zentaris Inc  Press Release , 2010:June 29 , <i>Article type: Commercial</i></p>
<p>1111047  Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer  Aeterna Zentaris Inc  Press Release , 2010:June 28 , <i>Article type: Commercial</i></p>
<p>1109722  Aeterna Zentaris Receives US\$12 Million on Closing of Registered Direct Offering  Aeterna Zentaris Inc  Press Release , 2010:June 21 , <i>Article type: Commercial</i></p>
<p>1109518  Company news in brief</p>

<p>Thomson Reuters IDdb Alert , 2010:June 22 , <i>Article type: Commercial</i></p>
<p><b>1109455</b> Aeterna Zentaris Presents Positive Data at ENDO Meeting on AEZS-130, a Ghrelin Mimetic for Diagnostic and Therapeutic Use AEterna Zentaris Inc Press Release , 2010:June 21 , <i>Article type: Commercial</i></p>
<p><b>1108242</b> Aeterna Zentaris to Raise US\$12 Million in Registered Direct Offering AEterna Zentaris Inc Press Release , 2010:June 15 , <i>Article type: Commercial</i></p>
<p><b>1108031</b> Company news in brief Thomson Reuters IDdb Alert , 2010:June 16 , <i>Article type: Commercial</i></p>
<p><b>1106491</b> Aeterna Zentaris Reports Final Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine in the Treatment of Advanced Metastatic Colorectal Cancer AEterna Zentaris Inc Press Release , 2010:June 08 , <i>Article type: Commercial</i></p>
<p><b>1106216</b> Aeterna Zentaris Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Including Patients with Advanced Brain Tumors and Neuroblastoma AEterna Zentaris Inc Press Release , 2010:June 07 , <i>Article type: Commercial</i></p>
<p><b>1106076</b> Aeterna Zentaris Presents Positive Efficacy and Safety Data for AEZS-108 in Ovarian Cancer at ASCO Meeting AEterna Zentaris Inc Press Release , 2010:June 07 , <i>Article type: Commercial</i></p>
<p><b>1100138</b> Aeterna Zentaris: Publication in the Journal of the National Cancer Institute Demonstrates Perifosine Single Agent Potential in Neuroblastoma Tumors Aeterna Zentaris Inc Press Release , 2010:May 17 , <i>Article type: Commercial</i></p>
<p><b>1100081</b> Regulatory news in brief Thomson Reuters IDdb Alert , 2010:May 18 , <i>Article type: Commercial</i></p>
<p><b>1100071</b></p>

Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency

Aeterna Zentaris Inc

Press Release , 2010:May 17 , *Article type: Commercial*

1099081

Financial results

Thomson Reuters

IDdb Alert , 2010:May 14 , *Article type: Commercial*

1098997

Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results

Aeterna Zentaris Inc

Press Release , 2010:May 13 , *Article type: Commercial*

1098738

Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer

Aeterna Zentaris Inc

Press Release , 2010:May 12 , *Article type: Commercial*

1096499

Regulatory news in brief

Thomson Reuters

IDdb Alert , 2010:May 07 , *Article type: Commercial*

1096462

Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer

Aeterna Zentaris Inc

Press Release , 2010:May 06 , *Article type: Commercial*

1094244

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aeterna Zentaris Inc

Press Release , 2010:April 27 , *Article type: Commercial*

1094083

Company news in brief

Thomson Reuters

IDdb Alert , 2010:April 28 , *Article type: Commercial*

1094016

Aeterna Zentaris Inc: Form 20-F for the financial year ended 31 December 2009

Aeterna Zentaris Inc

Form 20-F , 2010:March 30 , *Article type: Commercial*

1094015

Aeterna Zentaris Inc: Consolidated Financial Statements December 31, 2009, 2008 and 2007

<p>AEterna Zentaris Inc 4th Quarter Report , 2010:March 23 , <i>Article type: Commercial</i></p>
<p>1092162 Aeterna Zentaris Presents a Poster on its Dual Inhibitors for PI3K and Erk, as well as an Oral Presentation Reporting Data on Selective Erk Inhibitors, at AACR Annual Meeting AEterna Zentaris Inc Press Release , 2010:April 20 , <i>Article type: Commercial</i></p>
<p>1092068 Aeterna Zentaris: Poster Highlighting Preclinical Activity of Single-Agent Perifosine to be Presented at 2010 AACR Annual Meeting AEterna Zentaris Inc Press Release , 2010:April 20 , <i>Article type: Commercial</i></p>
<p>1091973 Company news in brief Thomson Reuters IDdb Alert , 2010:April 21 , <i>Article type: Commercial</i></p>
<p>1091951 Aeterna Zentaris Receives US\$15 Million on Closing of Registered Direct Offering AEterna Zentaris Inc Press Release , 2010:April 20 , <i>Article type: Commercial</i></p>
<p>1091810 AEterna Zentaris Inc AEterna Zentaris Inc Form 20-F , 2010:March 30 , <i>Article type: Commercial</i></p>
<p>1091050 Æterna Zentaris to Raise US\$15 Million in Registered Direct Offering AEterna Zentaris Inc Press Release , 2010:April 15 , <i>Article type: Commercial</i></p>
<p>1090954 Regulatory news in brief Thomson Reuters IDdb Alert , 2010:April 16 , <i>Article type: Commercial</i></p>
<p>1090953 Company news in brief Thomson Reuters IDdb Alert , 2010:April 16 , <i>Article type: Commercial</i></p>
<p>1090836 AEterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Program with Perifosine in Multiple Myeloma AEterna Zentaris Inc</p>



Press Release , 2010:April 15 , *Article type: Commercial*

1088613

Keryx begins phase III colorectal cancer study of perifosine

AEterna Zentaris Inc

Press Release , 2010:April 08 , *Article type: Commercial*

1087264

AEterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for the Treatment of Refractory Advanced Colorectal Cancer

AEterna Zentaris Inc

Press Release , 2010:April 05 , *Article type: Commercial*

1087216

AEterna Zentaris Inc form 40-F

AEterna Zentaris Inc

Company Publication , 2006:March 26 , *Article type: Commercial*

1085288

AEterna Zentaris Company website and Pipeline

AEterna Zentaris Inc

Company World Wide Web site , 2010:March 25 , *Article type: Commercial*

1085202

Financial results

Thomson Reuters

IDdb Alert , 2010:March 25 , *Article type: Commercial*

1085080

AEterna Zentaris Reports Fourth Quarter and Full-Year 2009 Financial and Operating Results

AEterna Zentaris Inc

Press Release , 2010:March 24 , *Article type: Commercial*

1078064

AEterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for Perifosine for the Treatment of Multiple Myeloma from the Committee for Orphan Medicinal Products of the European Medicines Agency

AEterna Zentaris Inc

Press Release , 2010:March 01 , *Article type: Commercial*

1072814

AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer

AEterna Zentaris Inc

Press Release , 2010:February 03 , *Article type: Commercial*

1071727

AEterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia

AEterna Zentaris Inc

Press Release , 2010:January 29 , *Article type: Commercial*

**1071725**

Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia

Keryx Biopharmaceuticals Inc

Press Release , 2010:January 29 , *Article type: Commercial*

**1070640**

Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer

AEterna Zentaris Inc

Press Release , 2010:January 25 , *Article type: Commercial*

**1070435**

Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price

AEterna Zentaris Inc

Press Release , 2010:January 22 , *Article type: Commercial*

**1070341**

Company news in brief

Thomson Reuters

IDdb Alert , 2010:January 25 , *Article type: Commercial*

**1068258**

JADO TECHNOLOGIES LICENSES CLINICAL DATA FROM AETERNA ZENTARIS FOR USE OF MILTEFOSINE IN ALLERGY INDICATIONS

JADO Technologies GmbH

Press Release , 2010:January 10 , *Article type: Commercial*

**1064944**

sanofi-aventis and AEterna Zentaris terminate agreement for cetorelix in the US

AETERNA ZENTARIS INC

Press Release , 2009:December 18 , *Article type: Commercial*

**1064501**

AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma

AEterna Zentaris Inc

Press Release , 2009:December 16 , *Article type: Commercial*

**1062672**

Investor Presentation: Aeterna Zentaris

AEterna Zentaris Inc

Company Presentation , 2009:November 30 , *Article type: Commercial*

**1062462**

AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology

AEterna Zentaris Inc

Press Release , 2009:December 07 , *Article type: Commercial*

**1062429**

AEterna drops cetorelix for BPH after failure to meet phase III primary endpoint

AEterna Zentaris Inc

Press Release , 2009:December 07 , *Article type: Commercial*

**1061549**

AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma

AEterna Zentaris Inc

Press Release , 2009:December 02 , *Article type: Commercial*

**1061527**

Regulatory news in brief

Thomson Reuters

IDdb Alert , 2009:December 03 , *Article type: Commercial*

**1056217**

Financial results

Thomson Reuters

IDdb Alert , 2009:November 12 , *Article type: Commercial*

**1056207**

AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results

Aeterna Zentaris Inc

Press Release , 2009:November 11 , *Article type: Commercial*

**1055631**

AEterna Zentaris: Scientific Article Supports Perifosine's Development in Kidney Cancer

AEterna Zentaris Inc

Press Release , 2009:November 09 , *Article type: Commercial*

**1053559**

AEterna's AEZS-108 meets primary endpoint in phase II ovarian cancer trial

AEterna Zentaris Inc

Press Release , 2009:November 02 , *Article type: Commercial*

**1051614**

AEterna Zentaris Receives US\$5.5 Million from Institutional Investors

AEterna Zentaris Inc

Press Release , 2009:October 23 , *Article type: Commercial*

**1050687**

Company news in brief

<p>Thomson Reuters IDdb Alert , 2009:October 21 , <i>Article type: Commercial</i></p>
<p>1050524 AEterna Zentaris to Raise US\$5.5 Million from Institutional Investors at US\$1.20 Per Share AEterna Zentaris Inc Press Release , 2009:October 19 , <i>Article type: Commercial</i></p>
<p>1046043 AEterna Zentaris: Thorough QT Trial with Cetrorelix in Benign Prostatic Hyperplasia Meets Primary Endpoint AEterna Zentaris Inc Press Release , 2009:September 30 , <i>Article type: Commercial</i></p>
<p>1045636 Æterna Zentaris Partner, Keryx, Presented Updated Phase 2 Data on Perifosine (KRX-0401) for the Treatment of Advanced Metastatic Renal Cell Carcinoma at 8th International Kidney Cancer Symposium in Chicago AEterna Zentaris Inc Press Release , 2009:September 29 , <i>Article type: Commercial</i></p>
<p>1043496 AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer AEterna Zentaris Inc Press Release , 2009:September 21 , <i>Article type: Commercial</i></p>
<p>1042254 AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma AEterna Zentaris Inc Press Release , 2009:September 16 , <i>Article type: Commercial</i></p>
<p>1042243 Regulatory news in brief Thomson Reuters IDdb Alert , 2009:September 17 , <i>Article type: Commercial</i></p>
<p>1034250 AEterna's cetrorelix misses efficacy endpoint in phase III benign prostatic hyperplasia trial AEterna Zentaris Inc Press Release , 2009:August 17 , <i>Article type: Commercial</i></p>
<p>1032993 AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results AEterna Zentaris Inc Press Release , 2009:August 11 , <i>Article type: Commercial</i></p>
<p>1032964 Financial results Thomson Reuters</p>

IDdb Alert , 2009:August 12 , <i>Article type: Commercial</i>
<p>1032085</p> <p>Company communication: Email</p> <p>AEterna Zentaris Inc</p> <p>Company Communication , 2009:August 06 , <i>Article type: Commercial</i></p>
<p>1030616</p> <p>Regulatory news in brief</p> <p>Thomson Reuters</p> <p>IDdb Alert , 2009:August 04 , <i>Article type: Commercial</i></p>
<p>1030612</p> <p>AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma</p> <p>AEterna Zentaris Inc</p> <p>Press Release , 2009:August 03 , <i>Article type: Commercial</i></p>
<p>1028042</p> <p>Drug development update: Lobaplatin</p> <p>AEterna Zentaris Inc</p> <p>Company Communication , 2009:July 24 , <i>Article type: Commercial</i></p>
<p>1023673</p> <p>AEterna's AEZS-123 shows preclinical promise for alcohol addiction</p> <p>AEterna Zentaris Inc</p> <p>Press Release , 2009:July 07 , <i>Article type: Commercial</i></p>
<p>1020986</p> <p>Company news in brief</p> <p>Thomson Reuters</p> <p>IDdb Alert , 2009:June 26 , <i>Article type: Commercial</i></p>
<p>1020832</p> <p>AEterna Zentaris Receives US\$10 Million from Institutional Investors</p> <p>AEterna Zentaris Inc</p> <p>Press Release , 2009:June 24 , <i>Article type: Commercial</i></p>
<p>1020090</p> <p>Q4 2008 Aeterna Zentaris Inc. Earnings Conference Call</p> <p>AEterna Zentaris Inc</p> <p>Company Presentation , 2009:March 11 , <i>Article type: Commercial</i></p>
<p>1019519</p> <p>AEterna Zentaris to Raise US\$10 Million from Institutional Investors at US\$1.88 Per Share</p> <p>AEterna Zentaris Inc</p> <p>Press Release , 2009:June 19 , <i>Article type: Commercial</i></p>
1019460

<p>Company news in brief Thomson Reuters IDdb Alert , 2009:June 22 , <i>Article type: Commercial</i></p>
<p><b>1018711</b> Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System Echo Therapeutics, Inc. Press Release , 2009:June 17 , <i>Article type: Commercial</i></p>
<p><b>1017936</b> AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule AEterna Zentaris Inc Press Release , 2009:June 15 , <i>Article type: Commercial</i></p>
<p><b>1016916</b> AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia AEterna Zentaris Inc Press Release , 2009:June 10 , <i>Article type: Commercial</i></p>
<p><b>1016440</b> AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer AEterna Zentaris Inc Press Release , 2009:June 08 , <i>Article type: Commercial</i></p>
<p><b>1016216</b> AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 AEterna Zentaris inc Press Release , 2009:June 08 , <i>Article type: Commercial</i></p>
<p><b>1015307</b> AEterna Zentaris Partner Keryx Reports Positive Phase 2 Data for Perifosine (KRX-0401) in Colon and Kidney Cancer at ASCO Meeting AEterna Zentaris Inc Press Release , 2009:June 01 , <i>Article type: Commercial</i></p>
<p><b>1014425</b> AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting AEterna Zentaris Inc Press Release , 2009:June 01 , <i>Article type: Commercial</i></p>
<p><b>1006595</b> Financial results Thomson Reuters IDdb Alert , 2009:May 07 , <i>Article type: Commercial</i></p>
<p><b>1006584</b></p>

<p>AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results AEterna Zentaris Inc Press Release , 2009:May 06 , <i>Article type: Commercial</i></p>
<p>1004380 Company news in brief Thomson Reuters IDdb Alert , 2009:April 30 , <i>Article type: Commercial</i></p>
<p>1004327 AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement AEterna Zentaris Inc Press Release , 2009:April 29 , <i>Article type: Commercial</i></p>
<p>1002338 AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver AEterna Zentaris Inc Press Release , 2009:April 22 , <i>Article type: Commercial</i></p>
<p>1001860 AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting AEterna Zentaris Inc Press Release , 2009:April 21 , <i>Article type: Commercial</i></p>
<p>991538 Protein Kinases – Eighth Annual Informa Congress (Part I), Barcelona, Spain, 3-4 March 2009 IDDb author IDdb Meeting Report , 2009:March 3-4 , <i>Article type: Review</i></p>
<p>984602 Anti-Angiogenic Agents - 11th International Symposium (Part II), San Diego, CA, USA, 5-7 February 2009 IDDb Author IDdb Meeting Report , 2009:February 5-7 , <i>Article type: Review</i></p>
<p>1180983 Protein Kinases – Informa's Tenth Annual Congress, Berlin, Germany, March 22-23, 2011 Knapp S IDdb Meeting Report , 2011:March 22-23 , <i>Article type: Review</i></p>
<p>1168566 GnRH - Tenth International Symposium, The Hypothalamic-Pituitary-Gonadal Axis in Cancer and Reproduction, Salzburg, Austria, February 6-8, 2011 Mettler L IDdb Meeting Report , 2011:February 6-8 , <i>Article type: Review</i></p>
<p>1154017</p>

American Society of Hematology - 52nd Annual Meeting and Exposition (PART I) – OVERNIGHT REPORT, Orlando, FL, USA, December 4-7 2010

Hodgkinson L, Tubby S

IDdb Meeting Report , 2010:December 4-7 , *Article type: Review*

**1149941**

Targeting the PI3K Pathway - CHI's Inaugural Conference, Boston, MA, USA, November 2-4, 2010

Iddb author

IDdb Meeting Report , 2010:November 2-3 , *Article type: Review*

**1096158**

Summary of American Association for Cancer Research - 101st Annual Meeting, Washington DC, USA, 17-21 April 2010

Whitty A

IDdb Meeting Report , 2010:April 17-21 , *Article type: Review*

**1094820**

American Association for Cancer Research - 101st Annual Meeting (Part VII), Washington DC, USA, 17-21 April 2010

Razvi ES

IDdb Meeting Report , 2010:April 17-21 , *Article type: Review*

**1092639**

Natural Peptides to Drugs - Fourth International Congress, Zermatt, Switzerland, 11-14 April 2010

Leone-Bay

IDdb Meeting Report , 2010:April 11-14 , *Article type: Review*

**1086994**

Protein Kinases - Informa's Ninth Annual Conference, Berlin, Germany, 17-18 March 2010

Moll J

IDdb Meeting Report , 2010:March 17-18 , *Article type: Review*

**1051683**

Ubiquitin Drug Discovery and Diagnostics 2009 – First Annual Conference, Philadelphia PA, USA, 13-14 October 2009

Marblestone JG

IDdb Meeting Report , 2009:October 13-14 , *Article type: Review*

**1022460**

Cancer – BIT Life Sciences' Second World Congress (Part I), Beijing, China, 22-25 June 2009

McKeown S

IDdb Meeting Report , 2009:June 22-25 , *Article type: Review*